We wish to inform you that the Board of Directors in their meeting held on August 14, 2025 have, inter-alia, noted, decided and approved the following matters:1. 30th AGM to be held on 29-09-2025 and other business matters.2. To close the register of members and share transfer books from September 23, 2025, to September 29, 2025 (both days inclusive) for the purpose of AGM.3. The appointment of Secretarial Auditors of the Company for Audit period of for a period of Five (5) consecutive years from financial year ("FY") 2025-26 to 2029-30.4. The re-appointment of Cost Auditors for the FY 2025-26.

Nectar Lifesciences reported weak Q1 FY26 results with revenue from operations falling to ₹280.67 crore from ₹358.85 crore a year ago, and swung to a net loss of ₹63.23 crore versus a profit of ₹2.97 crore in Q1 FY25, resulting in an EPS of ₹(2.82). The board approved the 30th AGM for September 29, 2025, with the share transfer register closed from September 23 to 29. M/s. P. Chadha & Associates was appointed as Secretarial Auditor for five years (FY26–FY30), while M/s. V. Kumar & Associates was re-appointed as Cost Auditor for FY26. Director Sanjiv Goyal was re-appointed on retirement by rotation. Importantly, a post-quarter note disclosed the sale of the company's entire API and formulations business to Ceph Lifesciences Private Limited for ₹1,270 crore on a slump sale basis, plus menthol business assets for ₹20 crore.